Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) announced participation in three investor conferences in June 2022. Events include the BTIG China Biotech Day on June 1, and the Jefferies Healthcare Conference from June 8-10, featuring a fireside chat on June 10 at 9:00 a.m. ET. Additionally, Gracell will attend the Citi 3rd Pan-Asia Regional Investor Conference during the same dates. The company focuses on developing advanced cell therapies for cancer, utilizing innovative technology platforms to tackle challenges associated with conventional CAR-T therapies.

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at three investor conferences in June 2022 as follows:

BTIG China Biotech Day (Virtual)

Fireside chat: June
One-on-one meetings: June 1
To listen to the live event, please contact your BTIG representative.

Jefferies Healthcare Conference

Fireside chat: June 10 at 9:00 a.m. Eastern Time
One-on-one meetings: June 8-10
Location: New York, NY
Webcast Link: https://ir.gracellbio.com/news-events/events-and-presentations   
The replay of the fireside chat can be accessed through the "News and Events" section of Gracell's investor website.

Citi 3^rd Pan-Asia Regional Investor Conference (Virtual)

One-on-one and small group meetings: June 8-10

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART^TM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-three-upcoming-investor-conferences-301550839.html

SOURCE Gracell Biotechnologies Inc.

FAQ

What investor conferences will Gracell Biotechnologies attend in June 2022?

Gracell Biotechnologies will attend the BTIG China Biotech Day on June 1, the Jefferies Healthcare Conference from June 8-10, and the Citi 3rd Pan-Asia Regional Investor Conference, also from June 8-10.

When is Gracell's fireside chat scheduled at the Jefferies Healthcare Conference?

Gracell's fireside chat at the Jefferies Healthcare Conference is scheduled for June 10, 2022, at 9:00 a.m. Eastern Time.

What is the focus of Gracell Biotechnologies?

Gracell Biotechnologies focuses on discovering and developing highly effective and affordable cell therapies for cancer treatment.

How does Gracell aim to address challenges in CAR-T therapies?

Gracell aims to overcome major challenges in conventional CAR-T therapies, such as lengthy manufacturing times and high costs, by utilizing its FasTCAR and TruUCAR technology platforms.

Where can I find more information about Gracell's investor events?

More information about Gracell's investor events can be found on their investor website at https://ir.gracellbio.com/news-events/events-and-presentations.